AZD0901 is an investigational medication being studied for its potential to treat advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. It is being tested to see if it can improve progression-free survival (PFS) and overall survival (OS) in patients who have already received other treatments. This medication targets a specific protein called Claudin 18.2, which is found in certain cancer cells, and aims to stop the cancer from growing or spreading.

Investigator’s Choice of Therapy refers to a selection of standard treatments that the doctor can choose from for the patient. These treatments are already approved and commonly used for treating advanced gastric or gastroesophageal junction adenocarcinoma. The choice depends on the patient’s previous treatments and overall health. The study compares the effectiveness of AZD0901 against these standard treatment options to see which works better for patients.

Gastric Cancer – Gastric cancer is a disease where malignant cells form in the lining of the stomach. It often begins in the mucus-producing cells on the inside of the stomach and can grow slowly over many years. As it progresses, the cancer may invade deeper layers of the stomach wall and spread to nearby organs or lymph nodes. Symptoms can include indigestion, stomach pain, nausea, and weight loss. The disease can be influenced by factors such as diet, smoking, and infections like Helicobacter pylori.

Advanced/Metastatic Gastric Cancer – This form of gastric cancer has spread beyond the stomach to other parts of the body. It is characterized by the cancer cells invading distant organs, such as the liver, lungs, or peritoneum. Symptoms may become more severe and include difficulty swallowing, vomiting, and significant weight loss. The progression of the disease can lead to complications like bleeding or obstruction in the stomach. It often requires more intensive management due to its widespread nature.

Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 – This is a specific type of cancer located where the stomach meets the esophagus, characterized by the expression of the protein Claudin18.2. It typically arises from glandular cells and can affect the lower esophagus and upper stomach. The disease may cause symptoms such as heartburn, difficulty swallowing, and chest pain. As it progresses, it can invade nearby tissues and spread to distant organs. The presence of Claudin18.2 can influence the behavior and treatment approach of the cancer.